Effects of eating dates on hunger and appetite in adults with Type 2 diabetes
Tip 2 Diyabetli Yetişkin Bireylerde Hurma Tüketiminin Hedonik Açlık ve İştah Hormonları Üzerine Etkilerinin İncelenmesi
This study tests if eating three Baghdad dates every day can help adults with Type 2 diabetes manage their hunger and appetite better over 12 weeks.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 64 (estimated) |
| Ages | 19 Years to 50 Years |
| Sex | All |
| Sponsor | Hacettepe University Academic / other |
| Locations | 1 site (Erzurum, Palandöken) |
| Trial ID | NCT06826235 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates how consuming three Baghdad dates daily affects hedonic hunger and appetite hormones in adults diagnosed with Type 2 diabetes. Participants will be randomly assigned to either an intervention group, which will include date consumption as part of their breakfast, or a control group that will not consume dates. The study aims to measure changes in appetite-related hormones and various health markers over a 12-week period. The research will also assess the impact of date consumption on lipid profiles and glycemic control in this population.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 19-50 with a diagnosis of Type 2 diabetes and a BMI between 25-35 kg/m2.
Not a fit: Patients with pre-diabetes, type 1 diabetes, or those with HbA1c levels above 10 may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a dietary intervention that helps manage appetite and improve metabolic health in individuals with Type 2 diabetes.
How similar studies have performed: While the specific effects of date consumption on appetite in Type 2 diabetes are not widely studied, similar dietary interventions have shown promise in managing metabolic conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals diagnosed with Type 2 diabetes aged 19-50 years (excluding menopausal women), * Individuals with BMI between 25-35 kg/m2, * Individuals with a Nutritional Strength Scale score of 2.5 and above, * Individuals who agreed not to start taking new dietary supplements or alternative therapies during the study period, * Individuals who agree not to change their current physical activity level and diet. Exclusion Criteria: * Individuals who do not approve the volunteer consent form, * Individuals with a Nutritional Strength Scale score below 2.5, * Pregnant or breastfeeding women (or women planning to become pregnant within 3 months) * Individuals with dietary energy \<800 kcal/day and \>4000 kcal/day, * Individuals with pre-diabetes, type 1 diabetes and gestational diabetes, * Individuals with HbA1c \>10 * Individuals taking antibiotics or hormone replacement therapy History of malignancy (except non-melanoma skin cancer). * Individuals with regular consumption of dates before inclusion in the study, * Individuals diagnosed with Type 2 diabetes using insulin and oral antidiabetic drugs with thiazolidinedione active substance, * Individuals with a history of diabetic ketoacidosis, diabetic coma or precoma within 6 months prior to the date of admission; serious infections, surgery, serious trauma requiring insulin treatment, haemodialysis treatment (including peritoneal haemodialysis), serious liver injury and serious vascular complications (stroke, myocardial infarction and heart failure) requiring hospitalisation, * Individuals taking pharmacological agents that have effects on appetite such as psychotropics, antiepileptics, antidepressants, antipsychotics and/or steroids, * Individuals diagnosed with eating disorders and/or psychological disorders, * Individuals with physical illnesses that affect eating behaviour or appetite, such as uncontrolled hyperthyroidism or hypothyroidism, Cushing's disease, acromegaly, adrenal insufficiency, chronic renal failure (stage 4 or 5), tuberculosis, human immunodeficiency virus (HIV) infection.
Where this trial is running
Erzurum, Palandöken
- Erzurum City Hospital — Erzurum, Palandöken, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Ayşe Çamli̇
- Email: aysecamli1996@gmail.com
- Phone: +905364254169
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.